Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 17/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.59 |
| ▸ | CDK4 | P11802 | 1/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.59 |
| ▸ | CCND1 | P24385 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | CCND3 | P30281 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | AXL | P30530 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144955 | 0.89 | ITK (0.73) | ITKCHEK1FGFR1 | |
| SCHEMBL145584 | 0.85 | ITK (1.00) | ITKCHEK1 | |
| SCHEMBL29470244 | 0.85 | ITK (1.00) | ITKCHEK1 | |
| SCHEMBL141689 | 0.83 | ITK (0.73) | ITKCHEK1FGFR1CDK4CCNA2 | |
| SCHEMBL145864 | 0.83 | ITK (1.00) | ITKCHEK1FGFR1CDK4CCNA2 | |
| SCHEMBL142590 | 0.83 | ITK (0.73) | ITKCHEK1FGFR1CDK4CCNA2 | |
| SCHEMBL141687 | 0.80 | ITK (0.64) | ITKCHEK1FGFR1CDK4CCNA2 | |
| SCHEMBL144359 | 0.80 | ITK (0.70) | ITKCHEK1FGFR1CDK4CCNA2 | |
| SCHEMBL3718413 | 0.80 | ITK (0.68) | ITKCHEK1FGFR1CDK4CCNA2 | |
| SCHEMBL144640 | 0.80 | ITK (1.00) | ITKCHEK1FGFR1CDK4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101884-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20050070546-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070546-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | ITK 377/4885CHEK1 499/4885FGFR1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.